Is Crawford & Co. overvalued or undervalued?

As of 13 August 2025, the valuation grade for Crawford & Co. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 18, a Price to Book Value of 3.33, and an EV to EBITDA of 4.20. In comparison, GoHealth, Inc. is considered risky with a P/E of 2.12, highlighting a significant disparity in valuation within the sector.
Crawford & Co. has demonstrated strong performance with a ROCE of 74.93% and a PEG ratio of 0.46, suggesting potential for growth relative to its price. However, its year-to-date return of -11.95% significantly underperformed the S&P 500's 12.22%, reflecting challenges in the current market environment. Overall, while the company is fairly valued, its recent stock performance indicates a need for caution.